(Alliance News) - Angle PLC on Monday said one of its leading customers, the Disseminated Cancer Cell Network, has published new results of work done to develop a "robust, reliable and cost-efficient workflow" for the enrichment of single-circulating tumour cells.
The liquid biopsy company said the Disseminated Cancer Cell Network researchers combined the use of Angle's Parsortix system with the micromanipulator CellCelector to enable single circulating tumour cells to be analysed individually to investigate the heterogeneity of the cancer, Angle said.
Angle's cell separation technology Parsortix enables a liquid biopsy to be used to provide the cells of interest to the user in a format suitable for multiple downstream subsequent analyses, said the company.
CellCelector is a freely configurable tool for the automated transfer of single cells and cell colonies.
Angle explained the work was undertaken in breast cancer and was able to detect varying gene expression between the individual circulating tumour cells as well as demonstrating changes in the patient's HER-2 expression can be detected.
"This new workflow provides a simple and effective approach to single-cell circulating tumour cell analysis, which is a developing area of research use for the Parsortix system. Investigation of gene expression and HER-2 status in breast cancer will be an important application of Parsortix following US Food & Drug Administration clearance," said Angle Founder & Chief Executive Andrew Newland.
Angle shares were trading 1.9% higher on Monday in London at 72.34 pence each.
Angle (AGL)